Generics for Galvus will be listed next month
By Kim, Jung-Ju | translator Choi HeeYoung
22.01.24 06:00:20
가나다라
0
Promotion of the MOHW's Amendment of the Drug Benefit List and the Upper Limit Table (Draft)
It can be sold immediately after changing the terms of the company's permission and completing approval from the MFDS
Price for Tamiflu Capsule 75mg was adjusted by 2.6% according to the actual transaction price survey of pharmacies
Generics, which had patent disputes with Galvus, a DPP-4 inhibitor-based diabetes treatment, will be listed in earnest next month. This is because companies applied for a change in permit conditions and the MFDS approved it, making it possible to sell it immediately.
According to the industry, the MOHW is pushing for a revision (proposal) of the drug benefit list on February 1. There are a total of five items available for registration next month, including Ahngook's Avusmet 50/500mg, Ahngook newpharm's Vildamet 50/500mg, Kyongbo's Vilda 50mg, Korea United Pharm's Healusmet, and Samjin's Vilguard M 50/500mg.
Earlier, these items completed the item approval process last year, but their regis
Kim, Jung-Ju(jj0831@dailypharm.com)
If you want to see the full article, please JOIN US (click)